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Available online 17 August 2015High-dose melphalan with autologous hematopoietic
stem-cell transplantation (HDM/SCT) prolongs survival and
induces hematologic and clinical responses in selected
patients with light-chain (AL) amyloidosis [1]. The optimal
dosing of melphalan in patients with a solitary functioning
kidney (SFK) and preserved glomerular filtration rate
(GFR) is unknown.
A 56-year-old Caucasian woman underwent left total
nephrectomy in 2007 due to complications of pyelonephri-
tis. She was found to have an M-protein spike during routine
health screening in 2008 and was diagnosed with IgG-lambda
monoclonal gammopathy of unknown significance. In 2012,she developed easy bruising, leg swelling, and periorbital
ecchymosis, followed by macroglossia, enlarged sub-
mandibular glands, and orthostatic hypotension. Further
investigation revealed nephrotic range proteinuria (5.9 g/
d). Kidney function measurements were: creatinine
0.82 mg/dL, creatinine clearance (CrCl) 94.9 mL/min by
Cockroft-Gault method, GFR 72.1 mL/min/1.73 m2 by Mod-
ification of Diet in Renal Disease method, and 24-h urine
CrCl 87 mL/min. Periorbital skin- and fat-pad biopsies
stained positive for Congo red, confirming AL amyloidosis
with renal, soft tissue, autonomic nervous system, and early
cardiac involvement.
The patient was treated with three cycles of CyBorD
(cyclophosphamide, bortezomib, dexamethasone) leading
to hematologic partial response. After comprehensive eval-
uation, the patient underwent stem cell mobilization with
granulocyte-colony stimulating factor 16 lg/kg/d  4 days
HDM/SCT in solitary kidney for AL amyloidosis 87and 5.0  106 CD34+ cells/kg were collected. The patient
received 200 mg/m2 of Melphalan IV over 2 days, in divided
doses on Days -3 and -2, and stem cell infusion on Day 0. The
post-SCT period was complicated by Grade 4 neutropenia,
thrombocytopenia, anemia, and Grade 3 febrile neutrope-
nia (toxicities graded according to National Cancer Institute
Common Terminology Criteria for Adverse Events, version
4.0). Neutrophil engraftment and platelet engraftment
was achieved at Day +10 and Day +13, respectively. Renal
function parameters remained stable until Day +22
(Figure 1).
At 6 months, a very good partial hematologic response
was achieved. Proteinuria had improved (4.7 g/24 h) andFigure 1 (a) Trend of creatinine clearance (CrCl), Cockroft-Gault
filtration rate (GFR), MDRD method, during peri-transplant period.
Figure 2 Creatinine clearance (CrCl) anrenal function parameters at 6 and 12 months post-HDM/
SCT were at baseline (Figure 2).
This is the first report detailing the renal outcome of a
patient with AL amyloidosis and a SFK who underwent
HDM/SCT with melphalan 200 mg/m2. Kidney function was
maintained throughout the peritransplantation period and
12 months after treatment. The patient tolerated treat-
ment well and adverse effects resolved by time of
engraftment.
The optimal dose of melphalan as conditioning regimen
in patients with a SFK is unknown. Patients with renal insuf-
ficiency suffer from more adverse effects. In multiple mye-
loma patients with renal failure, melphalan 140 mg/m2 maymethod during peri-transplant period. (b) Trend of glomerular
d GFR (MDRD) at 0, 6, and 12 months.
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ate analysis of a large AL amyloidosis series demonstrated
that patients who received 200 mg/m2 melphalan had bet-
ter survival rates relative to those receiving lower doses [3].
Acute kidney injury (AKI) occurs in 20% of patients under-
going HDM/SCT for AL amyloidosis [4]. This rate is higher
than in patients with multiple myeloma. There is lack of evi-
dence that having a SFK is a risk factor for developing AKI in
HDM/SCT. Nooka et al.[5] reported three multiple myeloma
patients with SFK who safely received 200 mg/m2 melphalan
[5]. In AL amyloidosis, older age, heavy proteinuria, hypoal-
buminemia, diuretic use, and a high urine sediment score
before treatment were risk factors for kidney injury [4].
Renal dysfunction should not preclude patients from HDM/
SCT, which can be effective and tolerable in selected
patients with end-stage renal disease, albeit with more tox-
icity [6].
HDM/SCT is associated with improved survival in AL amy-
loidosis. This case suggests that 200 mg/m2 melphalan is
safe and effective in patients with a solitary kidney and pre-
served function.
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